Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Outcome of Intravenous Thrombolysis for Stroke Patients in the 3-4.5 Hour Time Window

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified December 2014 by zhipeng xu, Wuhan General Hospital of Guangzhou Military Command.
Recruitment status was:  Enrolling by invitation
Sponsor:
Information provided by (Responsible Party):
zhipeng xu, Wuhan General Hospital of Guangzhou Military Command
ClinicalTrials.gov Identifier:
NCT01770197
First received: January 8, 2013
Last updated: December 9, 2014
Last verified: December 2014

January 8, 2013
December 9, 2014
January 2008
December 2014   (Final data collection date for primary outcome measure)
National Institute of Health Stroke Scale score and modified Rankin Scale [ Time Frame: Outcome measure will be assessed at 24 weeks ]
Favorable clinical outcome of intravenous recombinant tissue plasminogen activator was assessed by absolute changes in the National Institute of Health Stroke Scale score at 24 hours and by the improvement of modified Rankin Scale score at discharge or 6-month follow-up
Same as current
Complete list of historical versions of study NCT01770197 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Outcome of Intravenous Thrombolysis for Stroke Patients in the 3-4.5 Hour Time Window
The Feasibility and Outcome of Intravenous Thrombolysis for Stroke Patients in the 3-4.5 Hour Time Window in China
The time window for intravenous recombinant tissue plasminogen activator treatment in ischemic stroke patients has been extended to 4.5h. Little is known about intravenous recombinant tissue plasminogen activator use in the 3-4.5 hour time window among Chinese stroke patients. This exploratory study was to describe the feasibility and outcome of treatment with intravenous recombinant tissue plasminogen activator in the expanded time window, and to offer suggestions for future clinical work in China.
Favorable clinical outcome of intravenous recombinant tissue plasminogen activator was assessed by absolute changes in the National Institute of Health Stroke Scale score at 24 hours and by the improvement of modified Rankin Scale score at discharge or 6-month follow-up. The safety of intravenous recombinant tissue plasminogen activator was assessed by the rate of mortality, intracerebral hemorrhage and other common complications. Multivariate logistic regression models were used to evaluate factors associated with favorable clinical outcome.
Observational [Patient Registry]
Observational Model: Case Control
Time Perspective: Prospective
24 Weeks
Not Provided
Probability Sample
stroke patients in the 3-4.5 hour time window
Stroke
Drug: IV rt-PA
IV rt-PA treatment
Other Name: rt-PA
  • recombinant tissue plasminogen activator
    Stroke patients with rt-PA treatment in the 3-4.5 hour time window were compared with those within 3h.
    Intervention: Drug: IV rt-PA
  • rt-PA
    One group of was treated with standard recombinant tissue plasminogen activator therapy in 3h and the other group of stroke patients was treated within 3-4.5h.
    Intervention: Drug: IV rt-PA
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
200
December 2014
December 2014   (Final data collection date for primary outcome measure)

Inclusion Criteria:stroke patients in the 3-4.5 hour time window -

Exclusion Criteria:stroke patients in more than 4.5 hour time window

Sexes Eligible for Study: All
40 Years to 80 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT01770197
20090101
Yes
Not Provided
Not Provided
Not Provided
zhipeng xu, Wuhan General Hospital of Guangzhou Military Command
Wuhan General Hospital of Guangzhou Military Command
Not Provided
Study Chair: Wuhan G H, High Wuhan General Hospital of Guangzhou Command
Wuhan General Hospital of Guangzhou Military Command
December 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP